Strophanthidin

Strophanthidin is a naturally available cardiac glycoside[1]. Strophanthidin 0.1 and 1 nmol/L increases and 1~100 μmol/L inhibits the Na+/K+-ATPase activities, but Strophanthidin 10 and 100 nmol/L does not affect Na+/K+-ATPase activities in cardiac sarcolemmal[2]. Strophanthidin increases both diastolic and systolic intracellular Ca2+ concentration[3].

Product Specifications

CAS Number

[66-28-4]

Product Name Alternative

Splitomycin,Erythromycin Cyclocarbonate

UNSPSC

12352005

Hazard Statement

H300+H310+H330

Target

Na+/K+ ATPase

Type

Natural Products

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/strophanthidin.html

Purity

98.53

Solubility

Ethanol : 25 mg/mL (ultrasonic)

Smiles

O=C[C@@]12[C@]3([H])[C@](CC[C@@]1(C[C@@H](O)CC2)O)([H])[C@@]4([C@@](C)([C@@H](C5=CC(OC5)=O)CC4)CC3)O

Molecular Formula

C23H32O6

Molecular Weight

404.50

Precautions

H300+H310+H330

References & Citations

[1]Reddy D, et al. Strophanthidin Attenuates MAPK, PI3K/AKT/mTOR, and Wnt/β-Catenin Signaling Pathways in Human Cancers. Front Oncol. 2020;9:1469. Published 2020 Jan 17.|[2]Su SW, et al. Relationship between cardiotonic effects and inhibition on cardiac sarcolemmal Na+, K+-ATPase of strophan-thidin at low concentrations. Acta Pharmacol Sin. 2003;24 (11) :1103-1107.|[3]Bennett DL, et al. Strophanthidin-induced gain of Ca2+ occurs during diastole and not systole in guinea-pig ventricular myocytes. Pflugers Arch. 1999;437 (5) :731-736.